Search clinical trials for: ASC42

Total 19 results

Gannex Pharma Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
Gannex Pharma Co., Ltd.

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy Subjects

Healthy

United States
Ascletis Pharmaceuticals Co., Ltd.

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects

Healthy

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris

Acne Vulgaris

China
Ascletis Pharmaceuticals Co., Ltd.
Hunan Provincial People's Hospital

Completed

A Study of the Relative Bioavailability of ASC41 in Healthy Subjects

Healthy

China
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris

Acne

China
Gannex Pharma Co., Ltd.
Hunan Provincial People's Hospital

Completed

Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers

Healthy | NAFLD | Hyperlipidemia

China
Gannex Pharma Co., Ltd.

Recruiting

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH

Non-alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV

Hepatitis B, Chronic

China
Ascletis Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris

Acne
Gannex Pharma Co., Ltd.

Withdrawn

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH

Nonalcoholic Steatohepatitis (NASH)
Ascletis Pharmaceuticals Co., Ltd.
Peking University First Hospital; Beijing Clinical Service Center

Active, not recruiting

A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients

Chronic Hepatitis b

China
Shanghai Public Health Clinical Center

Recruiting

Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression

HIV Infections

China
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

HIV Infections | HIV-1-infection | PD-L1 Gene Mutation

China
Gannex Pharma Co., Ltd.

Completed

Drug Interaction Study of ASC42 With Atorvastatin

Healthy

United States
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Recurrent Glioblastoma

China
Gannex Pharma Co., Ltd.

Completed

DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.

Healthy | NAFLD

United States
Ascletis Pharmaceuticals Co., Ltd.

Completed

Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects

Healthy

China
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | HER2-positive Breast Cancer | Advanced Breast Carcinoma | HER2-Positive Breast Carcinoma

United States

3

Subscribe